Vazaprostan ampoule 60 mcg 10 pcs

Vasodilator, antiagregatsionnoe.

Vazaprostan – preparation of prostaglandin E1. Improves microcirculation and peripheral circulation.

Impact tone arteriolar sphincters and postcapillary, lowers systemic vascular resistance without changes in blood pressure, increase coronary blood flow and left ventricular ejection fraction.

It improves blood flow properties by reducing platelet adhesion and aggregation, reduce aggregation and improving erythrocyte deformability, improving fibrinolytic activity and reducing blood viscosity.

Influences on metabolism, increases glucose utilization and oxygen inhibits the release of free radicals and lysosomal enzymes from granulocytes and macrophages, stimulates the synthesis of proteins has a beneficial effect on lipid metabolism (inhibition of cholesterol synthesis and a reduction in LDL concentration), inhibits proliferation and mitosis smooth muscle cells.

The treatment Vazaprostanom decreases the severity of pain at rest, accelerates the healing of venous ulcers, occurs in the course of the disease in remission.

Active substance:
Alprostadil

Manufacturer

YUSB Pharma SA, Belgium

Prescribing

For adults on prescription

Composition

1 ampoule contains alprostadil (in the form of alpha-cyclodextrin) 60 mcg;

Excipients:

 lactose;

alfadeks.

Indications

microcirculatory disorders
Treatment of chronic occlusive arterial disease stages III and IV.

Contraindications

– Chronic heart failure in the stage of decompensation;
 – acute myocardial infarction and post-infarction period for 6 months;
 – The expressed disturbances of heart rhythm;
 – acute circulatory failure (shock, circulatory collapse);
 – marked hypotension (systolic blood pressure less than 90 mm Hg);
 – The expressed disturbances of liver function;
 – gastric ulcer and duodenal ulcer;
 – hypersensitivity to the drug.

Side effects

With the cardiovascular system: heart rate, hypotension, headache; in rare cases – increased frequency of angina attacks, pulmonary edema, heart failure events.

From the digestive system: dyspepsia, elevated liver transaminases.

Other: leukopenia, leukocytosis; long-term therapy (4 weeks) in rare cases, hyperostosis of long bones.

Local reactions: swelling, redness, pain at the injection site.

How to accept, acceptance rate and dosage

Vazaprostan may be administered in the / a and a / a.

To obtain a solution for intra-arterial administration 20 g (content of one ampoule) should be dissolved in 50 mL of saline. In conducting / infusion and 25 ml of the resulting solution (10 .mu.g of alprostadil) be administered during 60-120 min using a special device for the on / and infusion.

If necessary (particularly when necroses) the dose can be increased to 50 ml (20 g). If the introduction of the drug through a catheter installed in / and infusion is carried out for 12 hours at a dose of 0.1-0.6 ng / kg body weight per minute (corresponding to 12.5-25 vazaprostan ml solution).

To obtain a solution for intravenous administration of 40 mcg (contents of two vials) solids should be dissolved in 50-250 ml of physiological saline and the resulting solution was administered / drip for 2 hours, 2 times / day, or dissolved 60 g (content of 3 ampoules) 50-250 ml of physiological saline solution and administered i / v infusion over 3 hours, 1 time / day.

Patients with impaired renal function (creatinine concentration of more than 1.5 mg / dl) in / in a vazaprostan must begin with 10 mg of 2 times / day, each infusion duration – 2 hours
.

With good endurance for 2-3 days, the dose can be increased to normal. The duration of treatment should not exceed 4 weeks.

Storage conditions

The drug should be stored at temperatures not above 25 ° C.

Active substance

Alprostadil

Interaction

With simultaneous application Vazaprostan may enhance the hypotensive effect of antihypertensive agents, peripheral vasodilators, antianginal drugs.

The combined application vazaprostan with anticoagulants, antiplatelet agents increases the likelihood of hemorrhagic syndrome.

Special conditions

During treatment Vazaprostanom patients with signs of renal failure, and cardiac volume of liquid should be confined to 50-100 ml / day.

The therapy should be made to monitor blood pressure, heart rate, if necessary – the fluid balance control, measurement of central venous pressure holding echocardiography. Clinical efficacy of treatment is assessed after 3 weeks of therapy.

The therapy can be observed Vazaprostanom appearance of C-reactive protein in the biochemical Study on blood.

Overdose

Symptoms: reduced blood pressure, flushing of the skin, weakness.

Treatment: the infusion should be slowed down or stopped; if necessary symptomatic treatment.